Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial

被引：0
|
作者：
Staehler, M. [1 ]
Motzer, R. J. [2 ]
George, D. J. [3 ]
Pandha, H. S. [4 ]
Donskov, F. [5 ]
Escudier, B. [6 ]
Kliment, J. [7 ]
Pantuck, A. J. [8 ]
Patel, A. [9 ]
Deannuntis, L. [10 ]
Bhattacharyya, H. [11 ]
Lin, X. [12 ]
Lechuga, M. [13 ]
Serfass, L. [14 ]
Patard, J-J. [15 ]
Ravaud, A. [16 ]
机构：
[1] Univ Munich, Dept Urol, Munich, Germany
[2] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[3] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA
[4] Univ Surrey, Clin & Expt Med, Guildford, Surrey, England
[5] Aarhus Univ Hosp, Oncol, Aarhus, Denmark
[6] Inst Gustave Roussy, Villejuif, France
[7] Univ Hosp, Urol, Martin, Slovakia
[8] Ronald Reagan UCLA Med Ctr, Dept Urol, Los Angeles, CA USA
[9] Spire Roding Hosp, London, England
[10] Pfizer Inc, Collegeville, PA USA
[11] Pfizer Inc, New York, NY USA
[12] Pfizer Inc, La Jolla, CA USA
[13] Pfizer SrL, Milan, Italy
[14] Pfizer Oncol, Paris, France
[15] Ctr Hosp Mont De Marsan, Mont De Marsan, France
[16] Bordeaux Univ Hosp, Med Oncol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
855PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Pantuck, A. J.
    Patel, A.
    DeAnnuntis, L.
    Bhattacharyya, H.
    Ramaswamy, K.
    Zanotti, G.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Paty, J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2098 - 2104
  • [2] S-TRAC: UNDERSTANDING THE ADVERSE EVENT (AE) EXPERIENCE IN THE ADJUVANT TRIAL OF SUNITINIB FOR HIGH RISK RENAL CELL CARCINOMA (RCC)
    Wood, Sarah Yenser
    Ryan, Joanne C.
    Clair, Andrew G.
    George, Daniel
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [3] ADJUVANT SUNITINIB IN PATIENTS WITH HIGH RISK RENAL CELL CARCINOMA: SUBGROUP ANALYSES FROM S-TRAC TRIAL
    Pantuck, Allan
    Patard, Jean-Jacques
    Patel, Anup
    Ravaud, Alain
    Motzer, Robert J.
    Pandha, Hardev S.
    George, Daniel J.
    Chang, Yen-Hwa
    Escudier, Bernard
    Donskov, Frede
    Magheli, Ahmed
    Carteni, Giacomo
    Laguerre, Brigitte
    Tomczak, Piotr
    Breza, Jan
    Gerletti, Paola
    Lechuga, Mariajose
    Lin, Xun
    Casey, Michelle
    Staehler, Michael
    JOURNAL OF UROLOGY, 2017, 197 (04): : E62 - E63
  • [4] Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H. S.
    Staehler, M.
    George, D.
    Pantuck, A. J.
    Patel, A.
    Chang, Y-H.
    Escudier, B.
    Donskov, F.
    Magheli, A.
    Carteni, G.
    Laguerre, B.
    Tomczak, P.
    Breza, J.
    Gerletti, P.
    Lin, X.
    Lechuga, M.
    Martini, J-F.
    Patard, J-J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma
    Wood, Sarah Yenser
    Ryan, Joanne C.
    Clair, Andrew G.
    George, Daniel J.
    FUTURE ONCOLOGY, 2020, 16 (04) : 39 - 47
  • [6] Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials
    Gyawali, B.
    Ando, Y.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 898 - 899
  • [7] SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H.
    Staehler, M.
    George, D. J.
    Pantuck, A.
    Patel, A.
    Gerletti, P.
    Chen, L.
    Patard, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 292 - 293
  • [8] Sunitinib as adjuvant treatment in subjects with high risk renal cell carcinoma - A randomized double-blind phase 3 study (s-trac)
    Staehler, M.
    Roigas, J.
    ONKOLOGIE, 2008, 31 : 186 - 186
  • [9] Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial
    George, D. J.
    Pantuck, A. J.
    Figlin, R.
    Escudier, B.
    Halabi, S.
    Casey, M.
    Lin, X.
    Serfass, L.
    Frean, M. J. Lechuga
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 312 - 312
  • [10] Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC)
    Haas, Naomi B.
    Manola, Judith
    Ky, Bonnie
    Flaherty, Keith T.
    Uzzo, Robert G.
    Wood, Christopher G.
    Kane, Christopher J.
    Jewett, Michael A. S.
    Atkins, Michael B.
    Dutcher, Janice P.
    DiPaola, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345